In November 2025, China's state broadcaster CCTV News ran a plain-language explainer under a blunt headline: can the million-yuan anti-cancer needle actually clear cancer cells. It interviewed an academician, two clinicians and a cancer-association officer, and it answered the question the way a good clinician would. It is one of the better pieces written for the public on this subject, and it is the article families still forward to each other in group chats.
Two things have happened to it since. One claim in it has quietly stopped being true, which is the ordinary fate of anything written about a fast-moving field. And its closing warning has become more urgent rather than less, because the market it warned about has grown.
So this is not a summary of that report. It is a reading of it: what still holds, what has been overtaken, and which sentences a patient should act on.
The short version
What it is: not an injection at all, but an individually manufactured cell product made from the patient's own T cells. The Chinese name that has taken hold, anti-cancer needle, is a marketing artefact.
What it costs in China: roughly ¥0.90 to 1.29 million at list, which is 60 to 75 percent below the list price of the same therapy in the United States.
Who it is approved for: nine products in China as of October 2026, covering three myeloma, two B-cell leukaemia, three lymphoma and one gastric indication. Every one of them sits after standard treatment has failed.
What it is not: a general cure. Nine approvals cover a small fraction of cancer diagnoses, and the solid-tumour frontier is one narrow gastric label, not a breakthrough across the category.
What the Anti-Cancer Needle Actually Is
The report opens with Academician Fan Daiming of the Chinese Academy of Engineering, who is also president of the China Anti-Cancer Association, explaining why people normally do not get cancer. The answer is immunity, and immunity is mostly lymphocytes. A tumour grows when those lymphocytes fail to kill the malignant cells. CAR-T takes the lymphocytes out of the equation as a fixed quantity: you modify them so they can recognise and kill what they previously could not.
The broadcaster set the process out in five verbs, which is still the clearest short description of the therapy in Chinese or English:
- Collect. Ordinary immune T cells are taken from the patient's blood by apheresis.
- Arm. Genetic engineering gives each cell a chimeric antigen receptor, described in the report as a GPS guidance head plus an activation switch.
- Expand. The modified cells are multiplied outside the body until there are enough of them to matter.
- Infuse. They go back into the patient the way a blood transfusion does.
- Fight. Inside the body they hunt cells carrying the matching marker and destroy them.
Dr Lu Meng, a deputy chief physician in the haematology department at Peking University People's Hospital, supplied the sentence that best explains why this cannot be a product on a shelf. Every patient's CAR-T cells are cultured from that patient's own cells, she said, which makes each batch a medicine that exists nowhere else in the world.
That single fact governs almost everything else in this article: the price, the timeline, the side effects, and why a counterfeit version is not merely ineffective but unpredictable.
Read our full explainer on what CAR-T is and how the cells are made.
Why a Course Costs More Than a Million Yuan
The report gives four reasons and does not dress them up. The first is the personalisation itself: one batch, one patient, no economies of scale, and no way to overproduce in anticipation of demand. The second is manufacturing complexity, which in practice means a cleanroom, a viral or non-viral gene delivery step, and a release-testing panel that has to certify identity, purity, potency and sterility before anything is infused. The third is the cost of the clinical development programme, amortised over a patient population measured in hundreds rather than millions. The fourth is regulation and supply chain: chain-of-identity tracking, cryogenic shipping, and a hospital that can hold a bed and staff it.
None of those costs fall away when a product wins approval. What falls away is the trial infrastructure, which is why approved prices settle where they do rather than dropping sharply. In China they have settled lower than almost anywhere else. The cheapest CD19 product on the market is now about ¥899,000, and the first solid-tumour product came in at ¥990,000, both below the ¥1.16 to 1.29 million that the earliest entrants still charge.
See the current list prices and payment routes for all nine approved products in China.
What It Is Approved For, and the Rule That Decides Eligibility
At the time of the broadcast, fifteen CAR-T products had been approved worldwide, seven in the United States and eight in China. Dr Lu broke the Chinese eight down: three for multiple myeloma, two for B-cell acute lymphoblastic leukaemia, and the remainder for lymphoma.
The line-of-therapy rule she described is the part patients most often get wrong, and it has not changed. CAR-T in China is not a first-choice treatment. It is what happens after the standard options have been tried and have failed. Lymphoma has to have reached second or third line. Myeloma has to have reached fourth line. Leukaemia has to have run through two standard courses of chemotherapy without achieving remission.
The rule is not bureaucratic caution. It reflects the evidence base: the trials that won these approvals enrolled patients who had already exhausted conventional therapy, so that is the population in which the benefit has actually been measured. Outside that population, the risk-benefit calculation has not been established, which is a different statement from saying the therapy would not work.
The Sentence That Has Since Expired
The report's central limitation is stated twice, by two different specialists: for solid tumours, which are the large majority of cancers, CAR-T remained at the research stage worldwide. Professor Zhang Guojun of the China Anti-Cancer Association's breast cancer committee drew the line explicitly, putting breast, liver and colorectal cancer on the solid side and leukaemia and lymphoma on the blood side, with efficacy proven only for the latter.
In November 2025 that was accurate. It is no longer entirely accurate.
On 22 June 2026, China's regulator approved 恺力美 (satricabtagene autoleucel, satri-cel, CT041) for advanced gastric or gastro-oesophageal junction adenocarcinoma that is Claudin18.2-positive and HER2-negative, after at least two prior lines of treatment. It is the first CAR-T product anywhere in the world approved for a solid tumour. Seven months after the broadcast, the sentence that closed the door on solid tumours had a door in it.
The honest version of the claim today is narrower than either the original report or the enthusiasm that followed the approval. One product, one target, one disease. In the pivotal randomised trial, median progression-free survival was 3.25 months against 1.77 months for physician's choice, with an objective response rate of 22 percent against 4 percent. Overall survival showed a trend that did not cross the conventional significance threshold. That is a real result in a disease with few options, and it is not a cure.
See which solid tumours now have an approval and which remain trial-only.
The Side Effects Nobody Should Gloss Over
The report is unusually direct here, and it is the section most worth keeping. Because the therapy is a living cell treatment, the fight it conducts inside the body can produce cytokine release syndrome: persistent high fever, falling blood oxygen, falling blood pressure. And because the cells can cross into the central nervous system, patients may develop agitation or mania, coma, or seizures.
Dr Lu also gave the number that separates a good centre from an average one. Experienced hospitals, she said, have brought the rate of severe complications down to 10 percent or even below 5 percent. That figure is not a property of the drug. It is a property of the institution: whether there is a dedicated cell-therapy ward, whether tocilizumab and steroids are on hand and released without a pharmacy delay, whether there is an intensive care bed that can be occupied the same hour, and whether the nursing team has seen enough of these patients to recognise the syndrome before it escalates. A centre that treats a handful of cases a year cannot quote the same number.
The report also raises the point most commercial material omits. Regulators abroad have identified rare cases in which the CAR gene itself contributed to a second, separate cancer, and the United States Food and Drug Administration has written that risk into product labelling. For a patient with relapsed disease and no remaining conventional option, the trade-off may still be worth taking. But it is a trade-off, not a side-effect-free upgrade, and it belongs in the consent conversation.
| What can go wrong | What it looks like | What the centre must have ready |
|---|---|---|
| Cytokine release syndrome | Persistent high fever, falling oxygen saturation, falling blood pressure | Tocilizumab and steroids available without delay; monitored inpatient bed |
| Neurological toxicity | Agitation or mania, reduced consciousness, seizures | Neurology input, imaging on demand, intensive care access |
| No response or relapse | Disease continues or returns after an initial response | An honest pre-treatment conversation about what the data shows |
| Second malignancy | A separate cancer arising later, linked in rare cases to the gene insertion | Long-term follow-up, and disclosure of the risk before consent |
Where the Real Danger Sits: What Is Being Sold Online
The final third of the broadcast is the part that has aged in the opposite direction. Its reporters found that once CAR-T became a trending topic, individuals began advertising anti-cancer needles for sale, and clinics and private parties offering cell therapy for cancer appeared alongside them. The specialists' advice was blunt: do not throw money at something because the situation is desperate.
The regulatory position has since tightened. Under the State Council's regulation on the management of biotechnology, CAR-T and comparable new technologies were brought into the full regulatory system from 2026. A product outside that system has not been through the certification process and is not part of an approved clinical trial, which means its toxicities are not merely unproven but unpredictable. There is no release testing to certify what is in the bag, no dose that anyone has characterised, and no recourse if the patient is harmed.
For a family under pressure, the practical question is how to tell the two apart. Five checks settle most cases:
- A named product with an approval number. Every legitimate CAR-T in China is a specific branded product with a national approval and a label that states one or more named indications. If nobody can tell you the product name and what it is approved for, there is nothing to evaluate.
- Hospital pharmacy issue, not a handover. The product is released by the hospital's pharmacy with a batch record and chain-of-identity documentation. It is not delivered in a cold box by a salesperson.
- Apheresis and infusion in a licensed centre. Collection and infusion happen in a hospital with a cell-therapy programme, an inpatient bed, and an intensive care pathway. A hotel room, a clinic without inpatient beds, or a schedule that never mentions admission are all disqualifying.
- Written consent naming the product. Consent should name the product, its approved indication, the expected serious risks, and the alternatives. A consent form that promises clearance of cancer cells is a warning sign, not a reassurance.
- Payment to an institution. Money goes to the hospital against an invoice. A request to transfer funds to an individual's personal account, or to pay a broker before any assessment, ends the conversation.
What This Means If You Are Considering Treatment in China
For readers outside China, three practical points follow from the report and from the approvals since.
The first is price. The figures above are Chinese list prices, and the reimbursement layers behind them, including the national insurance scheme and the city-level supplementary schemes, require Chinese residency and local enrolment. International patients are normally quoted at list price plus hospital service fees. That is still typically 60 to 75 percent below the list price of the same therapy in the United States, but it is not the reimbursed number that Chinese residents sometimes quote online.
The second is availability. The therapy exists only where there is a licensed cell-therapy centre with apheresis capacity, a manufacturing slot, and a bed. That is a shorter list than the list of hospitals that treat cancer, and the solid-tumour product is shorter still.
The third is time. From first contact to infusion typically runs in weeks, not days: pathology review, target testing, eligibility assessment, apheresis, a manufacturing period of roughly three to five weeks, bridging treatment if the disease is moving, and then the infusion itself. Anyone offering to compress that into a week is skipping steps that exist for a reason.
This is a reading of published reporting and approvals, not a treatment recommendation.
It draws on the CCTV News report of 26 November 2025, on the national approvals in force as of 31 October 2026, and on the published trial data behind them. Figures are quoted as reported. Nothing here predicts an individual outcome, and eligibility for any therapy depends on the individual case and on the protocol in force at the treating centre. This article is educational and is not medical advice.
Source: CCTV News, 26 November 2025, interviewing Academician Fan Daiming (Chinese Academy of Engineering; China Anti-Cancer Association), Dr Lu Meng (Peking University People's Hospital, haematology) and Professor Zhang Guojun (China Anti-Cancer Association, breast cancer committee); national product approvals current to 31 October 2026.